Page last updated: 2024-09-03

lestaurtinib and Hormone-Dependent Neoplasms

lestaurtinib has been researched along with Hormone-Dependent Neoplasms in 2 studies

Research

Studies (2)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	1 (50.00)	18.2507
2000's	1 (50.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Bologna, M; Festuccia, C; Gravina, GL; Muzi, P; Pomante, R; Ricevuto, E; Ventura, L; Vicentini, C	1
Angeles, T; Dionne, CA; George, DJ; Isaacs, JT; Jani, J; Lamb, J; Murakata, C	1

Other Studies

2 other study(ies) available for lestaurtinib and Hormone-Dependent Neoplasms

Article	Year
In vitro and in vivo effects of bicalutamide on the expression of TrkA and P75 neurotrophin receptors in prostate carcinoma. The Prostate, 2007, Sep-01, Volume: 67, Issue:12 Topics: Adult; Aged; Androgen Antagonists; Anilides; Antineoplastic Agents; Blotting, Western; Carbazoles; Carcinoma; Cell Line, Tumor; Cohort Studies; Dihydrotestosterone; Furans; Humans; Immunohistochemistry; Indoles; Male; Middle Aged; Neoadjuvant Therapy; Neoplasms, Hormone-Dependent; Nitriles; Prostatic Neoplasms; Protein Kinase Inhibitors; Receptor, Nerve Growth Factor; Receptor, trkA; Receptor, trkC; Tosyl Compounds	2007
Sustained in vivo regression of Dunning H rat prostate cancers treated with combinations of androgen ablation and Trk tyrosine kinase inhibitors, CEP-751 (KT-6587) or CEP-701 (KT-5555). Cancer research, 1999, May-15, Volume: 59, Issue:10 Topics: Adenocarcinoma; Administration, Oral; Androgens; Animals; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Carbazoles; Combined Modality Therapy; Drug Screening Assays, Antitumor; Drug Synergism; Furans; Indoles; Injections, Subcutaneous; Leuprolide; Male; Neoplasm Proteins; Neoplasm Transplantation; Neoplasms, Hormone-Dependent; Orchiectomy; Prostatic Neoplasms; Proto-Oncogene Proteins; Rats; Receptor Protein-Tyrosine Kinases; Receptor, trkA; Receptors, Nerve Growth Factor	1999

Article

Year

In vitro and in vivo effects of bicalutamide on the expression of TrkA and P75 neurotrophin receptors in prostate carcinoma.

The Prostate, 2007, Sep-01, Volume: 67, Issue:12

Topics: Adult; Aged; Androgen Antagonists; Anilides; Antineoplastic Agents; Blotting, Western; Carbazoles; Carcinoma; Cell Line, Tumor; Cohort Studies; Dihydrotestosterone; Furans; Humans; Immunohistochemistry; Indoles; Male; Middle Aged; Neoadjuvant Therapy; Neoplasms, Hormone-Dependent; Nitriles; Prostatic Neoplasms; Protein Kinase Inhibitors; Receptor, Nerve Growth Factor; Receptor, trkA; Receptor, trkC; Tosyl Compounds

2007

Sustained in vivo regression of Dunning H rat prostate cancers treated with combinations of androgen ablation and Trk tyrosine kinase inhibitors, CEP-751 (KT-6587) or CEP-701 (KT-5555).

Cancer research, 1999, May-15, Volume: 59, Issue:10

Topics: Adenocarcinoma; Administration, Oral; Androgens; Animals; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Carbazoles; Combined Modality Therapy; Drug Screening Assays, Antitumor; Drug Synergism; Furans; Indoles; Injections, Subcutaneous; Leuprolide; Male; Neoplasm Proteins; Neoplasm Transplantation; Neoplasms, Hormone-Dependent; Orchiectomy; Prostatic Neoplasms; Proto-Oncogene Proteins; Rats; Receptor Protein-Tyrosine Kinases; Receptor, trkA; Receptors, Nerve Growth Factor

1999